1802326-66-4
 1802326-66-4 结构式
                        1802326-66-4 结构式
                    基本信息
3-氯-N-[2-氧代-2-[[(1S)-1-苯基乙基]氨基]乙基]苯甲酰胺
JNJ 63533054
JNJ-63533054 >=98% (HPLC)
JNJ-63533054 (JNJ63533054
3-Chloro-N-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]benzamide
Benzamide, 3-chloro-N-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-
物理化学性质
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 | 
| 2025/09/19 | S6425 | 3-氯-N-[2-氧代-2-[[(1S)-1-苯基乙基]氨基]乙基]苯甲酰胺 JNJ 63533054 | 1802326-66-4 | 5mg | 794.71元 | 
| 2025/05/22 | HY-19838 | 3-氯-N-[2-氧代-2-[[(1S)-1-苯基乙基]氨基]乙基]苯甲酰胺 JNJ-63533054 | 1802326-66-4 | 1 mg | 295元 | 
| 2025/05/22 | HY-19838 | 3-氯-N-[2-氧代-2-[[(1S)-1-苯基乙基]氨基]乙基]苯甲酰胺 JNJ-63533054 | 1802326-66-4 | 5mg | 650元 | 
常见问题列表
| Target | Value | 
| human GPR139 (Cell-free assay) | 0.024 μM(Ki) | 
| mouse GPR139 (Cell-free assay) | 0.054 μM(Ki) | 
| rat GPR13 (Cell-free assay) | 0.075 μM(Ki) | 
  JNJ-63533054 specifically activates human GPR139 in the calcium mobilization (EC
  
   50
  
  of 16 nM) and GTPγS binding (EC
  
   50
  
  of 17 nM) assays. JNJ-63533054 also activates the rat and mouse GPR139 receptor with similar potency (rat EC
  
   50
  
  of 63 nM, mouse EC
  
   50
  
  of 28 nM).
  
  In a saturation study for human GPR139, a single population of high-affinity binding sites for [3H] JNJ-63533054 is observed (K
  
   d
  
  of 10 nM). The B
  
   max
  
  value is 26 pmol/mg of protein. Saturation studies for the rat GPR139 and mouse GPR139 yielded K
  
   d
  
  values within the same range (32 nM and 23 nM, respectively; B
  
   max
  
  = 8.5 pmol/mg of protein and 6.2 pmol/mg of protein, respectively).
 
  JNJ-63533054 (3-30 mg/kg; oral administration; once; SD rats) treatment induces a dose-dependent reduction in locomotor activity in the first hour.
  
  The pharmacokinetics of JNJ-63533054 (Compound 7c; 1 mg/kg iv; 5 mg/kg po) in rat is examined. The IV clearance is 53 mL/min/kg, the C
  
   max
  
  is 317 ng/mL (~1 μM), the t
  
   1/2
  
  is 2.5 hours, and JNJ-63533054 is able to cross the blood-brain barrier (BBB) with a brain to plasma ratio (b/p) of 1.2.
 
| Animal Model: | Male Sprague-Dawley rats (350-450 g) | 
| Dosage: | 3 mg/kg, 10 mg/kg, and 30 mg/kg | 
| Administration: | Oral administration; once | 
| Result: | Induced a dose-dependent reduction in locomotor activity in the first hour. | 
 
                        